Skip to main content
Erschienen in: Journal of Infection and Chemotherapy 2/2010

01.04.2010 | Original Article

Suppression of phosphorylation of extracellular-signal-regulated kinase and p38 mitogen-activated protein kinase in polymorphonuclear leukocytes by the proton pump inhibitor lansoprazole

verfasst von: Osamu Koshio, Shigeru Tansho, Tsuneyuki Ubagai, Toshio Nakaki, Yasuo Ono

Erschienen in: Journal of Infection and Chemotherapy | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Lansoprazole (LPZ) is a proton pump inhibitor that suppresses gastric secretion and exerts anti-inflammatory effects on immune cells. Recently, LPZ has been used for the treatment of peptic ulcer and gastritis, which can be caused by Helicobacter pylori, due to its potent acid-suppressive effects. We focused the aim to the anti-inflammatory effects on the over-activation of neutrophils, and investigated the effects of LPZ on the signal transduction of the mitogen-activated protein kinase (MAPK) family. LPZ slightly phosphorylated p38 MAPK of neutrophils at a concentration of 10 μg/ml, but did not phosphorylate extracellular-signal regulated kinase (ERK) 1/2. Pretreatment of neutrophils with (1–5 μg/ml) LPZ strongly attenuated the phorbol-12-myristate-13-acetate-stimulated phosphorylation of ERK1/2, and LPZ slightly suppressed the lipopolysaccharide (LPS)- and N-formylmethionylleucylphenylalanine-stimulated phosphorylation of p38. ERK1/2 produces the mitochondrial anti-apoptotic proteins, and the signaling pathway from LPS and N-formylmethionylleucylphenylalanine to p38 is the main pathway for reactive oxygen species production. The mechanism of anti-inflammatory effect of LPZ on hyper-activated neutrophils is suggested to be the suppression of signal transduction of ERK1/2 and p38 MAPK.
Literatur
1.
Zurück zum Zitat Suzuki M, Suzuki H, Hibi T. Proton pump inhibitors and gastritis. J Clin Biochem Nutr. 2008;42:71–5.CrossRefPubMed Suzuki M, Suzuki H, Hibi T. Proton pump inhibitors and gastritis. J Clin Biochem Nutr. 2008;42:71–5.CrossRefPubMed
2.
Zurück zum Zitat Wandall JH. Effects of omeprazole on neutrophil chemotaxis, superoxide production, degranulation and translocation of cytochrome b-245. Gut. 1992;33:617–21.CrossRefPubMed Wandall JH. Effects of omeprazole on neutrophil chemotaxis, superoxide production, degranulation and translocation of cytochrome b-245. Gut. 1992;33:617–21.CrossRefPubMed
3.
Zurück zum Zitat Suzuki M, Nakamura M, Mori M, Miura S, Tsuchiya M, Ishii H. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol. 1995;20:S93–6.CrossRefPubMed Suzuki M, Nakamura M, Mori M, Miura S, Tsuchiya M, Ishii H. Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol. 1995;20:S93–6.CrossRefPubMed
4.
Zurück zum Zitat Suzuki M, Mori M, Fukumura D, Suzuki H, Miura S, Ishii H. Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extract of Helicobacter pylori. J Gastroenterol Hepatol. 1999;14:27–31.CrossRefPubMed Suzuki M, Mori M, Fukumura D, Suzuki H, Miura S, Ishii H. Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extract of Helicobacter pylori. J Gastroenterol Hepatol. 1999;14:27–31.CrossRefPubMed
5.
Zurück zum Zitat Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kasai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl. 1):74–81.CrossRefPubMed Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kasai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl. 1):74–81.CrossRefPubMed
6.
Zurück zum Zitat Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, Takagi T, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res. 2006;55:476–80.CrossRefPubMed Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, Takagi T, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res. 2006;55:476–80.CrossRefPubMed
7.
Zurück zum Zitat Ubagai T, Koshio O, Nakaki T, Ono Y. Down-regulation of immunological gene expressions in LPS-stimulated human polymorphonuclear leukocytes by a proton pump inhibitor, lansoprazole. J Infect Chemother. 2009;15:374–9. Ubagai T, Koshio O, Nakaki T, Ono Y. Down-regulation of immunological gene expressions in LPS-stimulated human polymorphonuclear leukocytes by a proton pump inhibitor, lansoprazole. J Infect Chemother. 2009;15:374–9.
8.
Zurück zum Zitat Crabtree JE, Wyatt JI, Trejdosiewicz LK, Peichl P, Nichols PH, et al. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol. 1994;47:61–6.CrossRefPubMed Crabtree JE, Wyatt JI, Trejdosiewicz LK, Peichl P, Nichols PH, et al. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol. 1994;47:61–6.CrossRefPubMed
9.
Zurück zum Zitat Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449–90.CrossRefPubMed Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449–90.CrossRefPubMed
10.
Zurück zum Zitat Lavigne LM, Albina JE, Reichner JS. β-Glucan is a fungal determinant for adhesion-dependent human neutrophil functions. J Immunol. 2006;177:8667–75.PubMed Lavigne LM, Albina JE, Reichner JS. β-Glucan is a fungal determinant for adhesion-dependent human neutrophil functions. J Immunol. 2006;177:8667–75.PubMed
11.
Zurück zum Zitat Suzuki K, Hino M, Kutsuna H, Hato F, Sakamoto C, Takahashi T, et al. Selective activation of p38 mitogen-activated protein kinase cascade in human neutrophils stimulated by IL-1β. J Immunol. 2001;167:5940–7.PubMed Suzuki K, Hino M, Kutsuna H, Hato F, Sakamoto C, Takahashi T, et al. Selective activation of p38 mitogen-activated protein kinase cascade in human neutrophils stimulated by IL-1β. J Immunol. 2001;167:5940–7.PubMed
12.
Zurück zum Zitat Brown GE, Stewart MQ, Bissonnette SA, Elia AEH, Wilker E, Yaffe MB. Distinct ligand-dependent roles for p38 MAPK in priming and activation of the neutrophil NADPH oxidase. J Biol Chem. 2004;279:27059–68.CrossRefPubMed Brown GE, Stewart MQ, Bissonnette SA, Elia AEH, Wilker E, Yaffe MB. Distinct ligand-dependent roles for p38 MAPK in priming and activation of the neutrophil NADPH oxidase. J Biol Chem. 2004;279:27059–68.CrossRefPubMed
13.
Zurück zum Zitat Koshio O, Ono Y. Effects of grepafloxacin on the function of human polymorphonuclear leukocytes and the phosphorylation of p38 mitogen-activated protein kinase. Chemotherapy (Barzel). 2009;55:363–71.CrossRef Koshio O, Ono Y. Effects of grepafloxacin on the function of human polymorphonuclear leukocytes and the phosphorylation of p38 mitogen-activated protein kinase. Chemotherapy (Barzel). 2009;55:363–71.CrossRef
14.
Zurück zum Zitat Choi IJ, Kim JS, Kim JM, Jung HC, Song IS. Effect of inhibition of extracellular signal-regulated kinase 1 and 2 pathway on apoptosis and bcl-2 expression in Helicobacter pylori-infected AGS cells. Infect Immun. 2003;71:830–7.CrossRefPubMed Choi IJ, Kim JS, Kim JM, Jung HC, Song IS. Effect of inhibition of extracellular signal-regulated kinase 1 and 2 pathway on apoptosis and bcl-2 expression in Helicobacter pylori-infected AGS cells. Infect Immun. 2003;71:830–7.CrossRefPubMed
15.
Zurück zum Zitat Suzuki H, Masaoka T, Minegishi Y, Motosugi Y, Miura S, Ishii H. Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen-activated protein kinase. Wound Rep Reg. 2004;12:93–9.CrossRef Suzuki H, Masaoka T, Minegishi Y, Motosugi Y, Miura S, Ishii H. Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen-activated protein kinase. Wound Rep Reg. 2004;12:93–9.CrossRef
16.
Zurück zum Zitat Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, et al. MAPKK-independent activation of p38α-mediated by TAB 1-dependent autophosphorylation of p38α. Science. 2002;295:1291–4.CrossRefPubMed Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, et al. MAPKK-independent activation of p38α-mediated by TAB 1-dependent autophosphorylation of p38α. Science. 2002;295:1291–4.CrossRefPubMed
17.
Zurück zum Zitat Ge B, Xiong XQ, Mosley JL, Filose A, Bian D, Huang S, et al. TAB 1β (transforming growth factor-β-activated protein kinase 1-binding protein 1β), a novel splicing variant of TAB 1 that interacts with p38α but not TAK1. J Biol Chem. 2003;278:2286–93.CrossRefPubMed Ge B, Xiong XQ, Mosley JL, Filose A, Bian D, Huang S, et al. TAB 1β (transforming growth factor-β-activated protein kinase 1-binding protein 1β), a novel splicing variant of TAB 1 that interacts with p38α but not TAK1. J Biol Chem. 2003;278:2286–93.CrossRefPubMed
18.
Zurück zum Zitat Dang PM, Stensballe A, Boussetta T, Raad H, Dewas C, Kroviarski Y, et al. A specific p47phox-serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest. 2006;116:2033–43.CrossRefPubMed Dang PM, Stensballe A, Boussetta T, Raad H, Dewas C, Kroviarski Y, et al. A specific p47phox-serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest. 2006;116:2033–43.CrossRefPubMed
19.
Zurück zum Zitat El-Benna J, Dang PM, Gougerot-Pocidalo M-A. Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol. 2008;30:279–89.CrossRefPubMed El-Benna J, Dang PM, Gougerot-Pocidalo M-A. Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol. 2008;30:279–89.CrossRefPubMed
20.
Zurück zum Zitat El-Benna J, Dang PM, Gougerot-Pocidalo MA, Marie JC, Braut-Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp Mol Med. 2009;41:217–25.CrossRefPubMed El-Benna J, Dang PM, Gougerot-Pocidalo MA, Marie JC, Braut-Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in diseases. Exp Mol Med. 2009;41:217–25.CrossRefPubMed
21.
Zurück zum Zitat Tanigawa T, Watanabe T, Higuchi K, Machida H, Okazaki H, Yamagami H, et al. Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-α and interleukin-1β induced by lipopolysaccharide and Helicobacter Pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-κB and extracellular signal-regulated kinase. J Clin Biochem Nutr. 2009;45:86–92.CrossRefPubMed Tanigawa T, Watanabe T, Higuchi K, Machida H, Okazaki H, Yamagami H, et al. Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-α and interleukin-1β induced by lipopolysaccharide and Helicobacter Pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-κB and extracellular signal-regulated kinase. J Clin Biochem Nutr. 2009;45:86–92.CrossRefPubMed
22.
Zurück zum Zitat Capodicasa E, De Bellis F, Pelli MA. Effect of lansoprazole on human leukocyte function. Immunopharmacol Immunotoxicol. 1999;21:357–77.CrossRefPubMed Capodicasa E, De Bellis F, Pelli MA. Effect of lansoprazole on human leukocyte function. Immunopharmacol Immunotoxicol. 1999;21:357–77.CrossRefPubMed
23.
Zurück zum Zitat Mikawa K, Akamatsu H, Nishina K, Niwa Y. Effects of pirenzepine, omeprazole, lansoprazole, and rabeprazole on human neutrophil functions. Can J Anaesth. 2001;48:421–2.PubMed Mikawa K, Akamatsu H, Nishina K, Niwa Y. Effects of pirenzepine, omeprazole, lansoprazole, and rabeprazole on human neutrophil functions. Can J Anaesth. 2001;48:421–2.PubMed
24.
Zurück zum Zitat Yeo M, Kim D-K, Kim Y-B, Oh TY, Lee J-E, Cho SW, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res. 2004;10:8687–96.CrossRefPubMed Yeo M, Kim D-K, Kim Y-B, Oh TY, Lee J-E, Cho SW, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res. 2004;10:8687–96.CrossRefPubMed
Metadaten
Titel
Suppression of phosphorylation of extracellular-signal-regulated kinase and p38 mitogen-activated protein kinase in polymorphonuclear leukocytes by the proton pump inhibitor lansoprazole
verfasst von
Osamu Koshio
Shigeru Tansho
Tsuneyuki Ubagai
Toshio Nakaki
Yasuo Ono
Publikationsdatum
01.04.2010
Verlag
Springer Japan
Erschienen in
Journal of Infection and Chemotherapy / Ausgabe 2/2010
Print ISSN: 1341-321X
Elektronische ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-009-0023-2

Weitere Artikel der Ausgabe 2/2010

Journal of Infection and Chemotherapy 2/2010 Zur Ausgabe

Announcement

JIC Award 2009

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.